Curacle entered a potential $1.07 billion deal with Memento Medicines, granting Memento exclusive global rights to develop and commercialize preclinical TIE2/VEGF-directed bispecific MT-103 for retinal disorders. Under the agreement, Curacle and strategic codeveloper Mabtics are set to receive an $8 million upfront payment plus development, regulatory, and commercialization milestones up to $1.06 billion. The structure reflects common ophthalmology partnering economics where early technical access is exchanged for larger milestone upside tied to clinical progress and market entry. The proceeds are split 50-50 between Curacle and Mabtics, according to the joint R&D framework described. For industry participants, the headline is the rights transfer for a preclinical asset focused on retinal angiogenesis pathways, which remains a commercially active region for bispecific strategies. The deal also signals continued appetite for retinal development assets where biomarker selection and trial design can be decisive for subsequent valuation.